Our Portfolio

Imperial College London

Paul Edison, MD, MRCP, PhD, FRCPI, FRCP | England, United Kingdom

Project Overview

  • Academic/Nonprofit Organization Type
  • $340,540 Funding Amount
  • 3/5/18 — 8/31/23 Project Duration
  • Clinical Program
  • Mitochondria/Metabolic Function Target
  • Clinical Phase 2 Therapeutic Stage
  • Active Status

Imperial College London

Paul Edison, MD, MRCP, PhD, FRCPI, FRCP | England, United Kingdom

Evaluating the effects of the novel GLP-I analogue, liraglutide, in patients with Alzheimer's disease (ELAD Study) - Open Label Extension

GET IN TOUCH